Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

30. April 2018 09:00 ET | Quelle: Provectus Biopharmaceuticals Inc.

STUDY OF T CELL MEDIATED IMMUNITY FROM COMBINATION OF PV-10 AND IMMUNE CHECKPOINT BLOCKADE IN MURINE MELANOMA MODELS PUBLISHED IN PLOS ONE

FOR IMMEDIATE RELEASE Combinations with PV-10 included + anti-CTLA-4; + anti-PD-1; + anti-PD-L1; and, + anti-PD-1 + Treg depletion Data provided basis for ongoing Phase 1b/2 study of PV-10 in...
25. April 2018 16:00 ET | Quelle: Provectus Biopharmaceuticals Inc.

PROVECTUS BIOPHARMACEUTICALS AND PEDIATRIC ONCOLOGY EXPERIMENTAL THERAPEUTICS INVESTIGATORS' CONSORTIUM (POETIC) ANNOUNCE ACCEPTANCE OF PV-10 POSTER PRESENTATION AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING

FOR IMMEDIATE RELEASE Preclinical pediatric cancer research undertaken at POETIC member institutions Alberta Children’s Hospital (Canada) and Memorial Sloan Kettering Cancer Center KNOXVILLE,...